A Phase II Study of CP-4055 plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-008518-38

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

1. Estimate rate of complete remission (CR), including complete remission except for platelet count < 100 x 109/L (CRp) (CR + CRp rate) in patients with AML who have not attained blast clearance after the first course of a ara-C based remission-induction therapy.


Critère d'inclusion

  • Acute Myeloid Leukaemia (AML)

Liens